Double-stranded ribonucleic acid with increased effectiveness in an organism

Details for Australian Patent Application No. 2004263830 (hide)

Owner Alnylam Pharmaceuticals, Inc.

Inventors Vornlocher, Hans-Peter; John, Matthias; Woppmann, Claudia; Hadwiger, Philipp

Agent Griffith Hack

Pub. Number AU-B-2004263830

PCT Pub. Number WO2005/014782

Priority 04002374.9 03.02.04 EP; 03013296.3 13.06.03 EP; 60/479,354 18.06.03 US

Filing date 14 June 2004

Wipo publication date 17 February 2005

Acceptance publication date 18 December 2008

International Classifications

C07H 21/04 (2006.01) Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids

C12N 15/11 (2006.01) Mutation or genetic engineering - DNA or RNA fragments

Event Publications

12 January 2006 PCT application entered the National Phase

  PCT publication WO2005/014782 Priority application(s): WO2005/014782

13 November 2008 Assignment before Grant

  Alnylam Europe AG The application has been assigned to Alnylam Pharmaceuticals, Inc.

18 December 2008 Application Accepted

  Published as AU-B-2004263830

23 April 2009 Standard Patent Sealed

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2004263832-Conserved HBV and HCV sequences useful for gene silencing

2004263829-Adhesion enhancing coating composition, process for using and coated or laminated articles produced